Biology and treatment of primary myelofibrosis.

@article{Hoffman2007BiologyAT,
  title={Biology and treatment of primary myelofibrosis.},
  author={Ronald A. Hoffman and Damiano Rondelli},
  journal={Hematology. American Society of Hematology. Education Program},
  year={2007},
  pages={
          346-54
        }
}
Primary myelofibrosis (PMF) is a chronic myeloproliferative disorder associated with an average survival of less than 5 years. Therapy for PMF has used chemotherapeutic agents, immunomodulatory drugs, or biological-response modifiers that have not always been directed at the biological processes that underlie the origins of PMF. Such strategies are palliative and have an uncertain effect on survival. At present, allogeneic stem cell transplantation (ASCT) is the only means of altering the… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 24 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 73 REFERENCES

A unique JAK2 mutation leading to constitute signaling causes polycythaemia vera

C James, V Ugo, JP Le Couedic
  • Nature
  • 2005
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Idiopathic myelofibrosis.

  • Seminars in hematology
  • 2005
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL